Form 4: Krystal Biotech CEO Krish Krishnan Executes Stock Sales Under 10b5-1 Trading Plan

Krystal Biotech's CEO, Krish Krishnan, and his spouse executed sales of common stock under pre-arranged Rule 10b5-1 trading plans.

Summary

• Krish S. Krishnan, the President and CEO of Krystal Biotech, Inc., reported the sale of common stock on September 12, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2024, which started on September 12, 2024, and will end on September 13, 2025.
• The plan contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share.
• Krishnan sold 3,957 shares at a weighted average price of $195.1627, 6,458 shares at $195.7226, 1,696 shares at $197.0387, 2,086 shares at $198.0803, 4,008 shares at $198.9264, 3,600 shares at $200.1522, 2,395 shares at $200.9758, and 800 shares at $201.8085.
• Following these transactions, Krishnan directly owns 1,562,262 shares of common stock.
• Krishnan's spouse, Suma M. Krishnan, also sold shares under a separate 10b5-1 trading plan.
• Suma M. Krishnan sold 8,497 shares at a weighted average price of $195.4297, 2,727 shares at $196.0668, 1,385 shares at $197.5454, 3,392 shares at $198.433, 2,945 shares at $199.2231, 4,159 shares at $200.4149, and 1,895 shares at $201.5177.
• Following these transactions, Suma M. Krishnan indirectly owns 1,500,882 shares.
• Krishnan also indirectly owns 90,000 shares through the Krishnan Spousal Trust and 50,000 shares through the Krishnan Family Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document reports insider selling, which can be viewed negatively, but it's under a pre-arranged plan, mitigating the concern. There are no explicit positive or negative statements about the company's performance.

Positives

• The sales are being conducted under a pre-arranged 10b5-1 trading plan, which can reassure investors that the transactions are not based on insider information.
• The trading plan has a limit price of $150.00, but the shares were sold for prices between $195 and $202, indicating that the market values the shares higher than the limit price.

Negatives

• The CEO and his spouse are selling shares, which could be perceived negatively by some investors, even though it's under a pre-arranged plan.
• The total number of shares sold by the CEO and his spouse is significant, which could put downward pressure on the stock price.

Risks

• Continued sales under the 10b5-1 trading plan could create ongoing selling pressure on the stock.
• Negative investor sentiment towards insider selling, even under a pre-arranged plan, could impact the stock price.
• The market price could drop below the $150 limit price in the trading plan, potentially affecting future sales.

Future Outlook

The CEO and his spouse will continue to sell shares under the 10b5-1 trading plan until September 13, 2025, with quarterly sales of up to 25,000 shares each, provided the stock price remains above $150.

Industry Context

Insider selling is a common occurrence, and the use of 10b5-1 trading plans is a standard practice to avoid accusations of trading on non-public information. Investors often monitor insider transactions for signals about a company's prospects, but pre-planned sales are generally viewed as less informative.

Comparison to Industry Standards

• Comparing Krystal Biotech's insider trading activity to companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, it's common to see executives utilize 10b5-1 plans for stock sales.
• The volume and frequency of these sales are generally in line with industry standards for companies of similar size and market capitalization.
• However, significant insider selling can sometimes raise concerns, especially if it deviates from established patterns or is not clearly explained by pre-arranged plans.

Stakeholder Impact

• Shareholders may react to the news of insider selling, potentially impacting the stock price.
• Employees may be concerned about the reasons behind the stock sales, although the 10b5-1 plan provides some reassurance.

Key Dates